Two newly approved respiratory syncytial virus (RSV) vaccines for adults age 60 years and older may be able to prevent illness in those at risk for severe RSV disease.

Most adult RSV illness occurs among the older age group and results in an estimated 60,000–160,000 hospitalizations and 6000–10,000 deaths a year among people at least 65 years old.

Older adults deciding whether to get the vaccines should weigh risks and their own preferences and make the decision in consultation with their clinician, say authors of a Centers for Disease Control and Prevention report published Friday.